RemeGen Announces US FDA Has Granted Breakthrough Therapy Designation for Disitamab Vedotin (RC48) in Urothelial Cancer

2020-09-25

RemeGen Co., Ltd. Announced New RC48-ADC Data in Patients with Advanced Gastric Cancer at ASCO

2020-06-17

荣昌生物正式入驻北京中海广场

2020-04-08
1 / 1

荣昌生物房健民:做特立独行的ADC,找准适应症不扎堆

2020-04-04

泰它西普:全球原创新药从烟台走向世界

2020-03-09

【山东新闻联播】荣昌生物:新药产业化撬动生物医药产业集群

2019-11-29
1 / 1
TwitterFacebook微博

Company Wechat

© All Right Reserved .  ICP:鲁ICP备11031710号-1